NeuBase Therapeutics Inc NBSE:NASDAQ

RT Quote | NASDAQ | USD
Last | 05/24/22 EDT
1.01quote price arrow up+0.01 (+1.00%)
Volume
102,353
52 week range
0.89 - 5.51
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.01
  • 52 Week High5.51
  • 52 Week High Date06/08/21
  • 52 Week Low0.89
  • 52 Week Low Date05/11/22

Key Stats

  • Market Cap32.58M
  • Shares Out32.26M
  • 10 Day Average Volume0.06M
  • Dividend-
  • Dividend Yield-
  • Beta0.81
  • YTD % Change-64.06

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.01
  • 52 Week High5.51
  • 52 Week High Date06/08/21
  • 52 Week Low0.89
  • 52 Week Low Date05/11/22
  • Market Cap32.58M
  • Shares Out32.26M
  • 10 Day Average Volume0.06M
  • Dividend-
  • Dividend Yield-
  • Beta0.81
  • YTD % Change-64.06

RATIOS/PROFITABILITY

  • EPS (TTM)-1.05
  • P/E (TTM)-0.97
  • Fwd P/E (NTM)-1.01
  • EBITDA (TTM)-32.591M
  • ROE (TTM)-107.81%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.43%

EVENTS

  • Earnings Date08/10/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On NeuBase Therapeutics Inc

There is no recent news for this security.

Profile

MORE
NeuBase Therapeutics, Inc. is a pre-clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to...
Dietrich Stephan Ph.D.
Chairman of the Board, President, Chief Executive Officer
William Mann Ph.D.
Chief Operating Officer
Todd Branning CPA
Chief Financial Officer
Address
350 Technology Drive
Pittsburgh, PA
15219-3124
United States

Top Peers

SYMBOLLASTCHG%CHG
ONCR
Oncorus Inc
1.25-0.04-3.10%
GLYC
GlycoMimetics Inc
0.58-0.0355-5.7677%
SPRB
Spruce Biosciences Inc
1.29-0.03-2.27%
RGLS
Regulus Therapeutics Inc
0.253+0.0078+3.18%
IMRA
Imara Inc
1.24-0.03-2.36%